化合物ARRY-403 T30142
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
100 mg | 1138669-65-4 | ¥49,700.00 | 询底价 |
10 mg | 1138669-65-4 | ¥18,800.00 | 询底价 |
1 mg | 1138669-65-4 | ¥6,970.00 | 询底价 |
5 mg | 1138669-65-4 | ¥13,900.00 | 询底价 |
50 mg | 1138669-65-4 | ¥37,700.00 | 询底价 |
25 mg | 1138669-65-4 | ¥27,800.00 | 询底价 |
Product Introduction
Bioactivity
英文名: ARRY-403
描述: ARRY-403 是一种新型葡萄糖激酶激活剂,可降低 2 型糖尿病患者的空腹和餐后血糖,可用于治疗糖尿病。
体内活性: Phase I studies have shown that ARRY-403 (AMG 151) activates glucokinase, a key enzyme in glucose homeostasis. The present randomized, placebo-controlled phase IIa study evaluated the dose-effect relationship of the glucokinase activator AMG 151 relative to placebo on fasting plasma glucose (FPG) in 236 patients (33-35 patients per arm) with type 2 diabetes treated with metformin. Patients received oral AMG 151 at 50, 100, or 200 mg twice daily, AMG 151 at 100, 200, or 400 mg once daily, or matching placebo for 28 days. A significant linear dose-effect trend was observed with the twice-daily regimen (p = 0.004) for change in FPG to day 28. No trend was observed with the once-daily regimen. A higher incidence of hypoglycemia and hypertriglyceridemia was observed with AMG 151 administration. AMG 151 significantly reduced FPG when administered twice daily but not when administered once daily in patients with type 2 diabetes treated with metformin.[1]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 50 mg/mL (110.01 mM)
相关产品: Dorzagliatin | Palmitelaidic Acid | KDM4-IN-2 | Tuberosin | Guajadial | AP-III-a4 | Cyclomusalenone | AZD-1656 | POMHEX | ML198
相关库: Drug Repurposing Compound Library | Bioactive Compounds Library Max | Kinase Inhibitor Library | Bioactive Compound Library
化合物ARRY-403 T30142信息由TargetMol中国为您提供,如您想了解更多关于化合物ARRY-403 T30142报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途